Search results
Added:
1 year ago
ESC Congress 2024 — Complete revascularisation is safe, reduces ischemic events for up to 4 years, and does not affect long-term mortality.We are joined onsite by Dr Gianluca Campo (University of Ferrara, Ferrara, IT) to discuss the findings from EARTH-STEMI. Previous RCTs have supported the benefit of complete revascularisation in the overall population, however, this has not been confirmed in…
View more
Added:
2 years ago
Added:
1 year ago
ACC.24 — Investigator, Dr Felix Böhm (Danderyd Hospital, SE) joins us to discuss the findings from a study investigating fractional flow reserve-guided complete or culprit-only percutaneous coronary intervention (PCI) in patients with ST-elevation myocardial infarction (MI).1542 patients were enrolled in the trial, who were randomized 1:1 to receive either FFR-guided PCI of non-culprit lesions…
View more
Added:
9 months ago
EuroPCR 25 - 10-year outcomes from DANAMI-3-PRIMULTI show FFR-guided complete revascularisation in ST-elevation myocardial infarction (STEMI) reduces the risk of future events. We are joined by Dr Thomas Engstrøm (University of Copenhagen, Copenhagen, Denmark) to discuss 10-year outcomes from the multicenter, randomized DANAMI-3-PRIMULTI trial investigating FFR-guided complete…
View more
Added:
9 months ago
EuroPCR 25 - 10-year follow-up findings of DANAMI-3-DEFER show a deferred stenting strategy may reduce HF hospitalisation in ST-elevation myocardial infarction (STEMI) patients.We are joined by Dr Jacob Lønborg (Rigshospitalet, Copenhagen, DK) to discuss key findings from the 10-year follow-up of the DANAMI-3-DEFER (NCT01435408) trial. This randomized controlled trial compared deferred stent…
View more
ESC 23: The RIGHT Study
Added:
2 years ago
Video
Added:
2 years ago
ESC 2023 — Prof Barbara Stähli (University Hospital Zurich, CH) joins us onsite at ESC 23 to outline the findings of the MULTISTARS AMI Trial (NCT03135275).
MULTISTARS AMI aimed to compare the safety and efficacy of two treatment strategies currently performed in clinical practice, immediate complete revascularization versus staged complete revascularization in patients presenting with ST…
View more
OPTION–STEMI: Immediate Complete Revascularisation Fails to Show Non-Inferiority to Staged Approach
Added:
6 months ago
Source:
Transcatheter Academy
News
Added:
4 months ago
Source:
Radcliffe Cardiology
The optimal timing for treating nonculprit lesions in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease remains a key clinical question. The iMODERN trial investigated whether an immediate intervention strategy was superior to a deferred approach in this patient population.¹The international, investigator-initiated, open-label iMODERN (Immediate or Deferred…
View more
Added:
4 months ago
Source:
Transcatheter Academy
The optimal timing for administering unfractionated heparin (UFH) to patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI) has been a topic of discussion. The HELP-PCI trial investigated whether pre-treatment with UFH at first medical contact (FMC) improves outcomes compared to administration in the catheterisation laboratory (Cath…
View more